Anti-ACLY/ ACL/ ATPCL monoclonal antibody
Anti-ACLY/ ACL/ ATPCL antibody for FACS & in-vivo assay
Go to ACLY/ACLY products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T52189-Ab-1/ GM-Tg-hg-T52189-Ab-2 | Anti-Human ACLY monoclonal antibody | Human |
GM-Tg-rg-T52189-Ab-1/ GM-Tg-rg-T52189-Ab-2 | Anti-Rat ACLY monoclonal antibody | Rat |
GM-Tg-mg-T52189-Ab-1/ GM-Tg-mg-T52189-Ab-2 | Anti-Mouse ACLY monoclonal antibody | Mouse |
GM-Tg-cynog-T52189-Ab-1/ GM-Tg-cynog-T52189-Ab-2 | Anti-Cynomolgus/ Rhesus macaque ACLY monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T52189-Ab-1/ GM-Tg-felg-T52189-Ab-2 | Anti-Feline ACLY monoclonal antibody | Feline |
GM-Tg-cang-T52189-Ab-1/ GM-Tg-cang-T52189-Ab-2 | Anti-Canine ACLY monoclonal antibody | Canine |
GM-Tg-bovg-T52189-Ab-1/ GM-Tg-bovg-T52189-Ab-2 | Anti-Bovine ACLY monoclonal antibody | Bovine |
GM-Tg-equg-T52189-Ab-1/ GM-Tg-equg-T52189-Ab-2 | Anti-Equine ACLY monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T52189-Ab-1/ GM-Tg-hg-T52189-Ab-2; GM-Tg-rg-T52189-Ab-1/ GM-Tg-rg-T52189-Ab-2; GM-Tg-mg-T52189-Ab-1/ GM-Tg-mg-T52189-Ab-2; GM-Tg-cynog-T52189-Ab-1/ GM-Tg-cynog-T52189-Ab-2; GM-Tg-felg-T52189-Ab-1/ GM-Tg-felg-T52189-Ab-2; GM-Tg-cang-T52189-Ab-1/ GM-Tg-cang-T52189-Ab-2; GM-Tg-bovg-T52189-Ab-1/ GM-Tg-bovg-T52189-Ab-2; GM-Tg-equg-T52189-Ab-1/ GM-Tg-equg-T52189-Ab-2 |
Products Name | Anti-ACLY monoclonal antibody |
Format | mab |
Target Name | ACLY |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-ACLY benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species ACLY/ ACL/ ATPCL VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | vGMLP005159 | human ACLY Lentivirus particle |
ORF Viral Vector | pGMLP005159 | human ACLY Lentivirus plasmid |
Target information
Target ID | GM-T52189 |
Target Name | ACLY |
Gene ID | 47,104112,24159,708501,607852,100422779,511135,100053195 |
Gene Symbol and Synonyms | A730098H14Rik,ACL,ACLY,ATPCL,CLATP |
Uniprot Accession | P53396,P16638,Q32PF2 |
Uniprot Entry Name | ACLY_HUMAN,ACLY_RAT,ACLY_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | N/A |
Gene Ensembl | ENSG00000131473 |
Target Classification | N/A |
The target: ACLY, gene name: ACLY, also named as ACL, ATPCL, CLATP. ATP citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. The enzyme is a tetramer (relative molecular weight approximately 440,000) of apparently identical subunits. It catalyzes the formation of acetyl-CoA and oxaloacetate from citrate and CoA with a concomitant hydrolysis of ATP to ADP and phosphate. The product, acetyl-CoA, serves several important biosynthetic pathways, including lipogenesis and cholesterogenesis. In nervous tissue, ATP citrate-lyase may be involved in the biosynthesis of acetylcholine. Multiple transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Dec 2014].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.